retatrutide update october 2025 Helped Adults With Obesity Lose Up to 30 Percent of Their Body Weight in New Trial retatrutide approval status october 2025

Vision loss may get worse before stabilizing and will likely have a low potential to improve

Some research suggests that AHK-Cu may offer protection against DHT-mediated damage through multiple pathways

This triple mechanism of action distinguishes it from existing agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP receptor agonist), and is thought to produce more pronounced effects on weight reduction and metabolic control

Concurrent federal action will provide the most robust protection against all the illegal and deceptive conduct. The statements issued by medical societies and government officials are important not just for health care professionals, but also for educating patients about how obesity management should be approached, according to Sangeeta Kashyap, MD, assistant chief of clinical affairs in the department of endocrinology, diabetes and metabolism at NewYork-Presbyterian/Weill Cornell Medical Center and a Healio | Endocrine Today Co-editor